Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · ACHIEVE LIFE SCIENCES, INC. (ACHV)

Achieve Life Sciences names Benjamin Halladay CFO, effective October 5, 2026

Neutral Impact 4 of 5 leadership Written later

Achieve Life Sciences said its board appointed Benjamin Halladay as Chief Financial Officer effective October 5, 2026, replacing Mark Oki, who is stepping down from the role on the same date. Mr. Halladay previously served as CFO of Esperion Therapeutics from November 2022 until September 2026, and the company said Mr. Oki's departure is not related to any disagreement over its financial statements or disclosures.

Key points

  • Benjamin Halladay appointed CFO and principal financial officer, effective October 5, 2026
  • Mark Oki steps down as CFO effective October 5, 2026; the company says there was no disagreement over financial statements or disclosures
  • Halladay offer letter includes $525,000 base salary, bonus of up to 40% of base salary, option for up to 200,000 shares and 200,000 restricted stock units
  • Full employment agreement text to be filed with the Form 10-Q for the quarter ending September 30, 2026

The filing

CompanyACHIEVE LIFE SCIENCES, INC. (ACHV)
Form8-K, current report
Filed with the SECOct 1, 2026, 4:49 PM ET
Accession number0001193125-26-410781

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:28 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 01, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.